DK0639374T3 - Nye behandlingsmetoder ved anvendelse af phenethylderivater - Google Patents

Nye behandlingsmetoder ved anvendelse af phenethylderivater

Info

Publication number
DK0639374T3
DK0639374T3 DK94304252T DK94304252T DK0639374T3 DK 0639374 T3 DK0639374 T3 DK 0639374T3 DK 94304252 T DK94304252 T DK 94304252T DK 94304252 T DK94304252 T DK 94304252T DK 0639374 T3 DK0639374 T3 DK 0639374T3
Authority
DK
Denmark
Prior art keywords
alkyl
hydrogen
disorder
syndrome
compound
Prior art date
Application number
DK94304252T
Other languages
Danish (da)
English (en)
Inventor
Richard Leslie Rudolph
Albert Thomas Derivan
Eric Anthony Muth
Gertrude Virginia Upton
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0639374(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of DK0639374T3 publication Critical patent/DK0639374T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK94304252T 1993-06-28 1994-06-13 Nye behandlingsmetoder ved anvendelse af phenethylderivater DK0639374T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8384893A 1993-06-28 1993-06-28

Publications (1)

Publication Number Publication Date
DK0639374T3 true DK0639374T3 (da) 2002-05-06

Family

ID=22181084

Family Applications (3)

Application Number Title Priority Date Filing Date
DK94304252T DK0639374T3 (da) 1993-06-28 1994-06-13 Nye behandlingsmetoder ved anvendelse af phenethylderivater
DK06017469T DK1738753T3 (da) 1993-06-28 1994-06-13 Nye behandlinger under anvendelse af phenethylaminderivater
DK01115854T DK1153603T3 (da) 1993-06-28 1994-06-13 Nye behandlingsmetoder ved anvendelse af phenethylaminderivater

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK06017469T DK1738753T3 (da) 1993-06-28 1994-06-13 Nye behandlinger under anvendelse af phenethylaminderivater
DK01115854T DK1153603T3 (da) 1993-06-28 1994-06-13 Nye behandlingsmetoder ved anvendelse af phenethylaminderivater

Country Status (16)

Country Link
US (8) US5916923A (fr)
EP (3) EP1153603B1 (fr)
JP (2) JPH0789851A (fr)
KR (1) KR100342762B1 (fr)
AT (3) ATE213407T1 (fr)
AU (2) AU6592994A (fr)
CA (1) CA2126305C (fr)
CY (1) CY2315B1 (fr)
DE (3) DE69429895T2 (fr)
DK (3) DK0639374T3 (fr)
ES (3) ES2174864T3 (fr)
HK (1) HK1038880B (fr)
LV (1) LV12881B (fr)
PT (3) PT639374E (fr)
PY (1) PY0101636A (fr)
SG (1) SG47711A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
EP1245228A3 (fr) * 1994-02-14 2002-10-09 Wyeth Venlafaxine et ses analogues pour induire une amélioration des fonctions cognitives
EP1331003B1 (fr) * 1996-03-25 2015-08-26 Wyeth LLC Composition de venlafaxine à libération prolongée
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
CA2337507A1 (fr) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition pour le traitement du stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
EP1464641B1 (fr) * 1999-12-30 2008-05-14 H. Lundbeck A/S Dérivés de 4-phenylpiperazinyle, -piperidinyle et -tetrahydropyridyle à titre de antagonistes de dopamine D4
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
FR2807753B1 (fr) * 2000-04-13 2002-06-07 Adir Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002250058B2 (en) * 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
CN1630631A (zh) * 2001-12-05 2005-06-22 惠氏公司 新的文拉法星盐酸盐多晶型物及其制备方法
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
AR039164A1 (es) 2002-03-28 2005-02-09 Synthon Bv Sales de venlafaxina de baja solubilidad en agua
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
WO2003082804A1 (fr) 2002-03-28 2003-10-09 Synthon B.V. Besylate de venlafaxine
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
CA2507685A1 (fr) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Procede de fabrication de microperles a liberation prolongee contenant de la venlafaxine hci
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
WO2004075902A1 (fr) * 2003-02-28 2004-09-10 Amedis Pharmaceuticals Ltd. Utilisation de derives de silicium de venlafaxine permettant de traiter ou de prevenir le psoriasis ou un trouble panique
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
RU2281788C2 (ru) * 2004-04-19 2006-08-20 Николай Иванович Косенков Способ ультрапарадоксальной психотерапии в лечении психосоматических заболеваний и измененных функциональных состояний человека
RU2276999C2 (ru) * 2004-05-06 2006-05-27 Анатолий Викторович Осницкий Метод коррекции психических состояний и лечения невротических расстройств и патологических зависимостей "интегрально-синергетическая психотерапия"
RU2270036C1 (ru) * 2004-07-14 2006-02-20 Государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии Министерства здравоохранения Российской Федерации" Способ коррекции психоэмоциональных и психосоматических расстройств у детей с термической травмой
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
RU2273498C1 (ru) * 2004-08-04 2006-04-10 Анатолий Анатолиевич Чумаченко Способ "табу" лечения зависимых форм поведения
RU2272657C1 (ru) * 2005-01-19 2006-03-27 Ирина Анатольевна Нелаева Способ информационно-трансового кодирования в лечении алкоголизма
US20060193911A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co., Controlled release venlafaxine formulations
CA2604915A1 (fr) * 2005-04-22 2006-11-02 Wyeth Nouvelles associations therapeutiques pour le traitement ou la prevention de la depression
TW200718692A (en) * 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
US7368477B2 (en) * 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
EP1879875A1 (fr) * 2005-04-22 2008-01-23 Wyeth Formes cristallines de {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}chlorhydrate amine
KR20080056311A (ko) * 2005-10-19 2008-06-20 테바 파마슈티컬 인더스트리즈 리미티드 고순도1-[2-디메틸아미노-(4-메톡시페닐)에틸)시클로헥산올염산염의 제조 방법
PT1954669E (pt) * 2005-12-01 2015-10-23 Auspex Pharmaceuticals Inc Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
CA2629609A1 (fr) 2005-12-05 2007-06-14 Wyeth Procede pour la synthese selective d'enantiomeres de 1-(2-amino-1-phenyl-ethyl)-cyclohexanols substitues
EP1998773A2 (fr) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Nouvelles combinaisons thérapeutiques pour le traitement de la dépression
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
AR063376A1 (es) * 2006-10-25 2009-01-28 Wyeth Corp Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento
SI2125698T1 (sl) 2007-03-15 2016-12-30 Auspex Pharmaceuticals, Inc. Devterirani d9-venlafaksin
US20090048233A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
US20110118304A1 (en) * 2007-11-20 2011-05-19 Neurosearch A/S Method for treating over-eating disorders
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
CZ301820B6 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
US20140118944A1 (en) * 2012-10-25 2014-05-01 Inhon International Co. Ltd. Electronic device
KR102132304B1 (ko) 2020-02-17 2020-07-09 박광순 접이식 유아용 비데
RU2741226C1 (ru) * 2020-09-08 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики агрессии лиц с интернет-зависимостью

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) * 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US3894051A (en) * 1973-07-05 1975-07-08 Colgate Palmolive Co N-methylenedioxyphenylalkyl)-{62 -(alkyl)-disubstituted phenethylamines
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4611078A (en) * 1983-10-26 1986-09-09 American Home Products Corporation Substituted phenylacetonitriles
US4609758A (en) * 1985-05-09 1986-09-02 American Home Products Corporation Phenoxyethylamine derivatives
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
JP2938463B2 (ja) * 1987-10-22 1999-08-23 マサチユセツツ・インスチチユート・オブ・テクノロジー 月経前又は後期黄体期症候群の処置
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5006525A (en) * 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
FI910897A7 (fi) * 1990-02-28 1991-08-29 Lilly Co Eli (S)-norfluoksetiiniin liittyviä parannuksia
CA2039103A1 (fr) * 1990-03-29 1991-09-30 David Wayne Robertson Ameliorations relatives a l'occupation selective des recepteurs 1c de la serotonine et ameliorations connexes
ATE244563T1 (de) * 1991-11-15 2003-07-15 Sepracor Inc Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives

Also Published As

Publication number Publication date
EP0639374A2 (fr) 1995-02-22
CY2315B1 (en) 2003-11-14
US20020052405A1 (en) 2002-05-02
PY0101636A (es) 2001-12-03
ES2304041T3 (es) 2008-09-01
JPH0789851A (ja) 1995-04-04
AU5831298A (en) 1998-05-21
EP1153603B1 (fr) 2006-10-18
PT1738753E (pt) 2008-06-19
EP1738753B1 (fr) 2008-04-23
DE69434872T2 (de) 2007-04-05
US20010053799A1 (en) 2001-12-20
ES2273764T3 (es) 2007-05-16
EP1153603A3 (fr) 2003-05-21
ATE342715T1 (de) 2006-11-15
US5916923A (en) 1999-06-29
US6465524B2 (en) 2002-10-15
DE69435095T2 (de) 2009-07-02
US20080176950A1 (en) 2008-07-24
DE69435095D1 (de) 2008-06-05
DE69429895T2 (de) 2002-08-29
EP1738753A3 (fr) 2007-01-31
PT639374E (pt) 2002-07-31
KR950000139A (ko) 1995-01-03
JP2006117689A (ja) 2006-05-11
EP0639374A3 (fr) 1995-08-02
DE69434872D1 (de) 2006-11-30
ATE392893T1 (de) 2008-05-15
US6555586B2 (en) 2003-04-29
AU6592994A (en) 1995-01-05
US20030181517A1 (en) 2003-09-25
PT1153603E (pt) 2007-01-31
US20040110829A1 (en) 2004-06-10
US6730706B2 (en) 2004-05-04
CA2126305A1 (fr) 1994-12-29
EP1738753A2 (fr) 2007-01-03
DK1738753T3 (da) 2008-08-11
KR100342762B1 (ko) 2002-11-18
ATE213407T1 (de) 2002-03-15
US6444708B2 (en) 2002-09-03
HK1038880B (en) 2006-12-22
EP1153603A2 (fr) 2001-11-14
DK1153603T3 (da) 2006-12-18
LV12881B (en) 2002-11-20
SG47711A1 (en) 1998-04-17
US20010012855A1 (en) 2001-08-09
HK1038880A1 (en) 2002-04-04
DE69429895D1 (de) 2002-03-28
EP0639374B1 (fr) 2002-02-20
ES2174864T3 (es) 2002-11-16
US6310101B1 (en) 2001-10-30
CA2126305C (fr) 2006-10-17

Similar Documents

Publication Publication Date Title
DK0639374T3 (da) Nye behandlingsmetoder ved anvendelse af phenethylderivater
NO942415L (no) Fremgangsmåte for fremstilling av behandling av surgass og hydrokarbonvæskeströmmer
RU99111492A (ru) N-замещенные 2-цианопирролидины
NZ280744A (en) Treatment of hypothalamic amenorrhea in non-depressed female mammals by administering an hydroxycycloalkanephenethylamine derivative
UA81413C2 (en) Methods of treating gastrointestinal and genitourinary pain disorders using vinlafaxin and derivatives
ATE413378T1 (de) Verfahren zur herstellung von phenylethylaminen, insbesondere venlafaxin
DE3864636D1 (de) Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen.
DK0667150T3 (da) Venlafaxin og dens analoger til fremkaldelse af en forbedring af de kognitive funktioner
PT82527B (pt) Processo para a preparacao de derivados de hidroxi-ciclo-alquil-fenoxi-etilamina
MY106786A (en) Novel antiviral tetrahydroimidazo [1,4] benzodiazepin -2- (thi)ones
ATE52776T1 (de) 1-phenyl-3-benzazepine.